Tuesday, April 26, 2011

FivePrime, Dyax enter antibody R&D deal

FivePrime Therapeutics Inc. will tap the libraries and technology of Dyax Corp. in a research deal aimed at developing and commercializing antibody drugs.
The value of the deal was not disclosed, but the collaboration could help privately held FivePrime, a South San Francisco-based developer of protein and antibody drugs in the areas of oncology, immunology and metabolic diseases, expand its pipeline of product candidates.

No comments:

Post a Comment